Literature DB >> 29948034

Does Prophylactic Ibuprofen After Surgical Atrial Septal Defect Repair Decrease the Rate of Post-Pericardiotomy Syndrome?

Edon J Rabinowitz1, David B Meyer2, Priya Kholwadwala3, Nina Kohn4, Adnan Bakar5,6.   

Abstract

Post-pericardiotomy syndrome (PPS) is an inflammatory process involving the pleura, pericardium, or both and occurs after cardiothoracic surgery. Surgical atrial septal defect (ASD) closure is associated with higher incidence of PPS post-operatively as compared to other operations. Reported incidence of PPS varies from 1 to 40%. NSAIDs are often used to treat PPS and in our center, some practitioners have prescribed ibuprofen prophylactically. This study sought to investigate the impact of prophylactic treatment with ibuprofen on the development and severity of PPS following surgical ASD closure, with particular attention to secundum-type ASDs. We retrospectively reviewed clinical and operative data of all surgical ASD repairs in our center from 1/2007 to 7/2017. ASDs were grouped by subtype. PPS was considered positive if the primary cardiologist diagnosed and documented clinical signs of PPS on post-operative outpatient follow-up. Records were reviewed to confirm documented diagnosis of PPS. A total of 245 cases were reviewed with 207 having sufficient data. Median age was 2 years (range 4 months-27 years), female 57%. Overall incidence of PPS was 10%. There was no difference in incidence of PPS in those prescribed ibuprofen as compared to those who were not. This was true for both the entire cohort and the subgroup analysis (P = 1.0). Four patients overall required pericardiocentesis, none of whom received prophylactic ibuprofen. Prophylactic ibuprofen prescription following surgical ASD repair did not reduce the rate of PPS in our cohort.

Entities:  

Keywords:  Atrial septal defect; Ibuprofen; Non-steroidal anti-inflammatory drugs; Post-cardiac injury syndrome; Post-pericardiotomy syndrome

Mesh:

Substances:

Year:  2018        PMID: 29948034     DOI: 10.1007/s00246-018-1926-4

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  A post-myocardial infarction syndrome; preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis.

Authors:  W DRESSLER
Journal:  J Am Med Assoc       Date:  1956-04-21

2.  Post-pericardiotomy syndrome in pediatric patients following surgical closure of secundum atrial septal defects: incidence and risk factors.

Authors:  Howard J Heching; Emile A Bacha; Leonardo Liberman
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

3.  Outcome following surgical closure of secundum atrial septal defect.

Authors:  D A Jones; D J Radford; P G Pohlner
Journal:  J Paediatr Child Health       Date:  2001-06       Impact factor: 1.954

4.  The effective treatment of postpericardiotomy syndrome after cardiac operations. A randomized placebo-controlled trial.

Authors:  P J Horneffer; R H Miller; T A Pearson; M F Rykiel; B A Reitz; T J Gardner
Journal:  J Thorac Cardiovasc Surg       Date:  1990-08       Impact factor: 5.209

5.  2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Yehuda Adler; Philippe Charron; Massimo Imazio; Luigi Badano; Gonzalo Barón-Esquivias; Jan Bogaert; Antonio Brucato; Pascal Gueret; Karin Klingel; Christos Lionis; Bernhard Maisch; Bongani Mayosi; Alain Pavie; Arsen D Ristic; Manel Sabaté Tenas; Petar Seferovic; Karl Swedberg; Witold Tomkowski
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

6.  Pericardial effusion after cardiac surgery in children and effects of aspirin for prevention.

Authors:  M J Béland; M Paquet; J E Gibbons; C I Tchervenkov; A R Dobell
Journal:  Am J Cardiol       Date:  1990-05-15       Impact factor: 2.778

7.  Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial.

Authors:  Massimo Imazio; Antonio Brucato; Paolo Ferrazzi; Alberto Pullara; Yehuda Adler; Alberto Barosi; Alida L Caforio; Roberto Cemin; Fabio Chirillo; Chiara Comoglio; Diego Cugola; Davide Cumetti; Oleksandr Dyrda; Stefania Ferrua; Yaron Finkelstein; Roberto Flocco; Anna Gandino; Brian Hoit; Francesco Innocente; Silvia Maestroni; Francesco Musumeci; Jae Oh; Amedeo Pergolini; Vincenzo Polizzi; Arsen Ristic; Caterina Simon; David H Spodick; Vincenzo Tarzia; Stefania Trimboli; Anna Valenti; Riccardo Belli; Fiorenzo Gaita
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

8.  The incidence and natural history of pericardial effusion after cardiac surgery--an echocardiographic study.

Authors:  L B Weitzman; W P Tinker; I Kronzon; M L Cohen; E Glassman; F C Spencer
Journal:  Circulation       Date:  1984-03       Impact factor: 29.690

9.  The effect of short-term prophylactic acetylsalicylic acid on the incidence of postpericardiotomy syndrome after surgical closure of atrial septal defects.

Authors:  Peter J Gill; Karen Forbes; James Y Coe
Journal:  Pediatr Cardiol       Date:  2009-07-28       Impact factor: 1.655

Review 10.  The postcardiac injury syndromes.

Authors:  A H Khan
Journal:  Clin Cardiol       Date:  1992-02       Impact factor: 2.882

View more
  3 in total

1.  Postpericardiotomy syndrome after cardiac surgery.

Authors:  Joonas Lehto; Tuomas Kiviniemi
Journal:  Ann Med       Date:  2020-05-02       Impact factor: 4.709

Review 2.  Recurrent Pericarditis in Children and Adolescents.

Authors:  Enrico Tombetti; Teresa Giani; Antonio Brucato; Rolando Cimaz
Journal:  Front Pediatr       Date:  2019-10-18       Impact factor: 3.418

Review 3.  The Efficacy of Corticosteroids, NSAIDs, and Colchicine in the Treatment of Pediatric Postoperative Pericardial Effusion.

Authors:  Nirmiti Somani; Hans Breur
Journal:  Pediatr Cardiol       Date:  2022-01-21       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.